Aryan Jamali, | |
30423 Canwood St Ste 225, Agoura Hills, CA 91301-4367 | |
(818) 871-9518 | |
(818) 871-9521 |
Full Name | Aryan Jamali |
---|---|
Gender | Female |
Speciality | Home Health |
Location | 30423 Canwood St Ste 225, Agoura Hills, California |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1013553858 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
363LF0000X | Nurse Practitioner - Family | 95012187 (California) | Secondary |
251E00000X | Home Health | 95012187 (California) | Primary |
Mailing Address | Practice Location Address |
---|---|
Aryan Jamali, 30423 Canwood St Ste 225, Agoura Hills, CA 91301-4367 Ph: (818) 871-9518 | Aryan Jamali, 30423 Canwood St Ste 225, Agoura Hills, CA 91301-4367 Ph: (818) 871-9518 |
News Archive
For the third consecutive year and fourth time in five years, The University of Texas M. D. Anderson Cancer Center is ranked the nation's top cancer hospital in U.S. News & World Report's "America's Best Hospitals" survey, published in the magazine's July 12 issue.
Rapid discontinuation of the immunosuppressive steroid prednisone after a kidney transplant can help prevent serious side effects, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology.
Two new papers published in Diabetologia (the journal of the European Association for the Study of Diabetes reveal the importance of both the amount and timing of physical activity in reducing the risk of developing type 2 diabetes (T2D), as well as aiding the management of the disease in existing T2D patients.
A blood vessel-blocking drug called tasquinimod slowed the rate of disease progression in a clinical trial of 200 prostate cancer patients, according to experts at Johns Hopkins, Roswell Park Cancer Institute and Duke University.
VeriChip Corporation announced today that it has entered into a strategic partnership with the Diabetes Research Institute ("DRI") to combine efforts on the further development of the glucose-sensing radio frequency identification (RFID) microchip in conjunction with VeriChip's development partner, RECEPTORS LLC.
› Verified 9 days ago